查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615419

基因組測試市場：按組件、技術、應用、分銷管道、最終用途分類 - 2025-2030 年全球預測

Genome Testing Market by Component (Consumables, Equipment, Software & Services), Technology (Microarrays, Next-Generation Sequencing, Targeted Sequencing), Application, Distribution Channel, End-use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年基因組檢測市值為175.7億美元，預計到2024年將達到197.6億美元，複合年成長率為13.21%，預計到2030年將達到419億美元。

基因組測試，包括基因型鑒定和定序，是現代醫療保健、研究和個人化醫療的寶貴工具。其範圍包括檢測疾病的遺傳傾向、確定治療策略和支持藥物開發。基因組測試的需求在於能夠根據個人的遺傳傾向進行個人化治療，實現早期疾病檢測和預防性護理，並改善患者的治療結果和成本效率。應用涵蓋各個領域，從臨床診斷和藥物研究到農業和家譜研究。最終用戶範圍從醫療保健提供者和研究機構到尋求個人化健康見解的消費者。

主要市場統計
基準年[2023] 175.7億美元
預測年份 [2024] 197.6億美元
預測年份 [2030] 419億美元
複合年成長率（%） 13.21%

由於技術進步、定序成本降低以及個人化醫療需求的增加，基因組測試市場正在迅速發展。關鍵的成長要素包括公眾對遺傳疾病的認知提高、政府支持措施以及精準醫學應用的擴大。機會包括開發可攜式基因組定序儀、將人工智慧和機器學習整合到基因組學中，以及擴大基因組學在醫療保健以外領域的使用，例如法醫學和生物資訊學。為了抓住這些機會，公司應該專注於開發方便用戶使用且負擔得起的測試解決方案和強大的資料分析平台。

然而，這個市場面臨著資料隱私問題、基因資料使用的道德問題以及跨地區缺乏標準化監管等限制。挑戰包括由於隱私問題和遺傳知識的潛在心理影響而阻礙消費者採用的障礙。成功減少這些障礙為創新創造了空間，特別是在加強資料保護措施和製定更清晰的法規結構。

為了實現持續成長，公司正在優先考慮 CRISPR 等基因組編輯技術的創新，探索與科技公司合作以推動數位健康解決方案，並揭示基因檢測的好處並確保道德。基因組檢測市場高度活躍，其特點是技術不斷進步，並逐漸轉向更全面、全面的健康解決方案。

市場動態：揭示快速發展的基因組測試市場的關鍵市場洞察

供需的動態交互作用正在改變基因組檢測市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 全球遺傳疾病和癌症盛行率不斷上升
    • 越來越重視疾病的早期發現與預防
    • 個人化醫療意識不斷增強
  • 市場限制因素
    • 與基因組設備相關的高成本
  • 市場機會
    • 基因序列測定和資料分析的技術進步
    • 增加政府措施和資金以促進研究活動
  • 市場挑戰
    • 與解釋遺傳訊息相關的複雜性

波特五力：駕馭基因組測試市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解基因組檢測市場的外部影響

外部宏觀環境因素在塑造基因組檢測市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解基因組檢測市場的競爭狀況

基因組測試市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV定位矩陣基因組測試市場供應商績效評估

FPNV定位矩陣是評估基因組檢測市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製基因組測試市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，基因組測試市場的策略分析至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 全球遺傳疾病和癌症的發生率正在增加
      • 疾病的早​​期發現和預防變得越來越重要
      • 個人化醫療意識不斷增強
    • 抑制因素
      • 與基因組設備相關的高成本
    • 機會
      • 基因序列分析與資料分析的技術進步
      • 政府加大力度和資助以促進研究活動
    • 任務
      • 與解釋遺傳訊息相關的複雜性
  • 市場區隔分析
    • 組成部分：高通量定序設備的不斷進步
    • 技術：準確、全面的基因組分析提高了次世代定序的普及度
    • 應用：增加對先進基因組測試的投資
    • 最終用途：先進基因組學在診斷實驗室中對遺傳疾病研究的重要性日益增加
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章 基因組測試市場：依組成部分

  • 消耗品
  • 裝置
  • 軟體和服務

第7章 基因組測試市場：依技術分類

  • 微陣列
  • 次世代定序
  • 標靶定序
  • 全基因組序列分析

第8章 基因組測試市場：依應用分類

  • 癌症
    • 腦腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 惡性黑色素瘤
    • 卵巢癌
    • 攝護腺癌
  • 非癌症
    • 心血管疾病
    • 神經系統疾病
    • 瘤

第9章 基因組測試市場：依分銷管道分類

  • 離線
  • 線上

第 10 章 基因組測試市場：依最終用途

  • 診斷實驗室
  • 醫院/診所

第11章 美洲基因組檢測市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章 亞太地區基因體檢測市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章 歐洲、中東、非洲基因組檢測市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Corn Health 為 100,000 人基因組計劃做準備
    • Illumina 推出先進的液態生物檢體技術，可對固態腫瘤進行全面的基因組分析
    • 阿波羅在清奈開設基因組研究所，並計劃在 2023 年再開設三所
  • 戰略分析和建議

公司名單

  • 10x Genomics
  • 23andMe, Inc
  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • BGI Group
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Eurofins Scientific SE
  • F. Hoffmann-La Roche, Ltd.
  • Freenome Holdings, Inc.
  • GeneDx, LLC
  • Genomic Testing Cooperative
  • Helix OpCo, LLC
  • Illumina, Inc.
  • Merck KGaA
  • New England Biolabs, Inc.
  • Novogene Co, Ltd.
  • Oxford Nanopore Technologies PLC
  • PerkinElmer Inc.
  • QIAGEN NV
  • Quest Diagnostics Incorporated
  • Takara Bio Inc
  • Thermo Fisher Scientific Inc.
  • Ultima Genomics, Inc.
  • VWR International, LLC
Product Code: MRR-647F3A880B41

The Genome Testing Market was valued at USD 17.57 billion in 2023, expected to reach USD 19.76 billion in 2024, and is projected to grow at a CAGR of 13.21%, to USD 41.90 billion by 2030.

Genome testing, encompassing both genotyping and sequencing, is an invaluable tool in modern healthcare, research, and personalized medicine. Its scope includes detecting genetic predispositions to diseases, guiding treatment decisions, and aiding in drug development. The necessity of genome testing is driven by its potential to personalize medical treatments based on an individual's genetic makeup, enabling early disease detection and preventative healthcare, which enhances patient outcomes and cost efficiency. Applications extend across various sectors, from clinical diagnostics and pharmaceutical research to agriculture and ancestry tracing. End users range from healthcare providers and research institutions to consumers seeking personalized health insights.

KEY MARKET STATISTICS
Base Year [2023] USD 17.57 billion
Estimated Year [2024] USD 19.76 billion
Forecast Year [2030] USD 41.90 billion
CAGR (%) 13.21%

The market for genome testing is rapidly evolving, spurred by technological advancements, decreasing costs of sequencing, and increasing demand for personalized medicine. Key growth influencers include increased public awareness of genetic diseases, supportive government initiatives, and expanding applications in precision medicine. Opportunities arise from the development of portable genome sequencers, integration of AI and machine learning in genomics, and expanding the use of genomics in non-healthcare fields such as forensic sciences and bioinformatics. To seize these opportunities, companies should focus on developing user-friendly, affordable testing solutions and robust data analytics platforms.

However, the market faces limitations such as data privacy concerns, ethical issues regarding genetic data usage, and a lack of standardized regulations across regions. Challenges include barriers to consumer adoption due to privacy worries and potential psychological impacts of genetic knowledge. Achievements in reducing these hurdles present room for innovation, particularly in enhancing data protection measures and in developing clearer regulatory frameworks.

For sustained growth, businesses should prioritize innovation in genome editing technologies like CRISPR, explore partnerships with technology firms to enhance digital health solutions, and invest in the educational outreach to demystify genetic testing benefits and address ethical concerns. The genome testing market is highly dynamic, marked by continuous advancements in technology and a gradual shift towards more comprehensive and integrated health solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Genome Testing Market

The Genome Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of genetic disorders and cancer across the globe
    • Growing emphasis on early disease detection & prevention
    • Increasing awareness of personalized medicine
  • Market Restraints
    • High cost associated with genomics equipment
  • Market Opportunities
    • Technological advancements in gene sequencing and data analysis
    • Rising government initiatives and fundings for boosting research activities
  • Market Challenges
    • Complexities associated with the interpreting genetic information

Porter's Five Forces: A Strategic Tool for Navigating the Genome Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Genome Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Genome Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Genome Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Genome Testing Market

A detailed market share analysis in the Genome Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Genome Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Genome Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Genome Testing Market

A strategic analysis of the Genome Testing Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Genome Testing Market, highlighting leading vendors and their innovative profiles. These include 10x Genomics, 23andMe, Inc, Abbott Laboratories, Agilent Technologies, Inc., BGI Group, Bio-Rad Laboratories, Inc., Danaher Corporation, Eurofins Scientific SE, F. Hoffmann-La Roche, Ltd., Freenome Holdings, Inc., GeneDx, LLC, Genomic Testing Cooperative, Helix OpCo, LLC, Illumina, Inc., Merck KGaA, New England Biolabs, Inc., Novogene Co, Ltd., Oxford Nanopore Technologies PLC, PerkinElmer Inc., QIAGEN N.V., Quest Diagnostics Incorporated, Takara Bio Inc, Thermo Fisher Scientific Inc., Ultima Genomics, Inc., and VWR International, LLC.

Market Segmentation & Coverage

This research report categorizes the Genome Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Consumables, Equipment, and Software & Services.
  • Based on Technology, market is studied across Microarrays, Next-Generation Sequencing, Targeted Sequencing, and Whole Genome Sequencing.
  • Based on Application, market is studied across Cancer and Non-cancer. The Cancer is further studied across Brain Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Melanoma, Ovarian Cancer, and Prostate Cancer. The Non-cancer is further studied across Cardiovascular Diseases, Neurological Disorders, and Tumors.
  • Based on Distribution Channel, market is studied across Offline and Online.
  • Based on End-use, market is studied across Diagnostic Laboratories and Hospitals & Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of genetic disorders and cancer across the globe
      • 5.1.1.2. Growing emphasis on early disease detection & prevention
      • 5.1.1.3. Increasing awareness of personalized medicine
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with genomics equipment
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in gene sequencing and data analysis
      • 5.1.3.2. Rising government initiatives and fundings for boosting research activities
    • 5.1.4. Challenges
      • 5.1.4.1. Complexities associated with the interpreting genetic information
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Component: Ongoing advancements in equipments for high-throughput sequencing
    • 5.2.2. Technology: Increasing preference of next-generation sequencing due to its precise and comprehensive genomic analysis
    • 5.2.3. Application: Increasing investment for advance genome testing across
    • 5.2.4. End-use: Rising significance of advanced genomic in diagnostic laboratories for research associated with genetic diseases
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Genome Testing Market, by Component

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Equipment
  • 6.4. Software & Services

7. Genome Testing Market, by Technology

  • 7.1. Introduction
  • 7.2. Microarrays
  • 7.3. Next-Generation Sequencing
  • 7.4. Targeted Sequencing
  • 7.5. Whole Genome Sequencing

8. Genome Testing Market, by Application

  • 8.1. Introduction
  • 8.2. Cancer
    • 8.2.1. Brain Cancer
    • 8.2.2. Breast Cancer
    • 8.2.3. Colorectal Cancer
    • 8.2.4. Lung Cancer
    • 8.2.5. Melanoma
    • 8.2.6. Ovarian Cancer
    • 8.2.7. Prostate Cancer
  • 8.3. Non-cancer
    • 8.3.1. Cardiovascular Diseases
    • 8.3.2. Neurological Disorders
    • 8.3.3. Tumors

9. Genome Testing Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Offline
  • 9.3. Online

10. Genome Testing Market, by End-use

  • 10.1. Introduction
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals & Clinics

11. Americas Genome Testing Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Genome Testing Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Genome Testing Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Cone Health Readies for 100,000 Person Genomics Project
    • 14.3.2. Illumina Launches Advanced Liquid Biopsy Assay to Enable Comprehensive Genomic Profiling of Solid Tumors
    • 14.3.3. Apollo Opens Genomic Institute In Chennai, to Open Three More in 2023
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 10x Genomics
  • 2. 23andMe, Inc
  • 3. Abbott Laboratories
  • 4. Agilent Technologies, Inc.
  • 5. BGI Group
  • 6. Bio-Rad Laboratories, Inc.
  • 7. Danaher Corporation
  • 8. Eurofins Scientific SE
  • 9. F. Hoffmann-La Roche, Ltd.
  • 10. Freenome Holdings, Inc.
  • 11. GeneDx, LLC
  • 12. Genomic Testing Cooperative
  • 13. Helix OpCo, LLC
  • 14. Illumina, Inc.
  • 15. Merck KGaA
  • 16. New England Biolabs, Inc.
  • 17. Novogene Co, Ltd.
  • 18. Oxford Nanopore Technologies PLC
  • 19. PerkinElmer Inc.
  • 20. QIAGEN N.V.
  • 21. Quest Diagnostics Incorporated
  • 22. Takara Bio Inc
  • 23. Thermo Fisher Scientific Inc.
  • 24. Ultima Genomics, Inc.
  • 25. VWR International, LLC

LIST OF FIGURES

  • FIGURE 1. GENOME TESTING MARKET RESEARCH PROCESS
  • FIGURE 2. GENOME TESTING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENOME TESTING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENOME TESTING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENOME TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENOME TESTING MARKET DYNAMICS
  • TABLE 7. GLOBAL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENOME TESTING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENOME TESTING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENOME TESTING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENOME TESTING MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENOME TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENOME TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENOME TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENOME TESTING MARKET SIZE, BY BRAIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENOME TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENOME TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENOME TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENOME TESTING MARKET SIZE, BY MELANOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENOME TESTING MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENOME TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENOME TESTING MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENOME TESTING MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENOME TESTING MARKET SIZE, BY TUMORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENOME TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENOME TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENOME TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENOME TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES GENOME TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 95. AUSTRALIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 101. CHINA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CHINA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 107. INDIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 108. INDIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. INDIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. INDONESIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 114. INDONESIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 115. INDONESIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 116. INDONESIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. JAPAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. JAPAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 121. JAPAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 122. JAPAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 123. JAPAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 125. MALAYSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 126. MALAYSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. MALAYSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 128. MALAYSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 129. MALAYSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. MALAYSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 131. PHILIPPINES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 132. PHILIPPINES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 133. PHILIPPINES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. PHILIPPINES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 135. PHILIPPINES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 136. PHILIPPINES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 137. PHILIPPINES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 138. SINGAPORE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 139. SINGAPORE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. SINGAPORE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SINGAPORE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 142. SINGAPORE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 143. SINGAPORE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 144. SINGAPORE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. SOUTH KOREA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. SOUTH KOREA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 147. SOUTH KOREA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. SOUTH KOREA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 149. SOUTH KOREA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 150. SOUTH KOREA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. SOUTH KOREA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 152. TAIWAN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 153. TAIWAN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 154. TAIWAN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 155. TAIWAN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 156. TAIWAN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 157. TAIWAN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. TAIWAN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 159. THAILAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 160. THAILAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. THAILAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. THAILAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 163. THAILAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 164. THAILAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 165. THAILAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. VIETNAM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 167. VIETNAM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. VIETNAM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. VIETNAM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 170. VIETNAM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 171. VIETNAM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 172. VIETNAM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 177. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 178. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 179. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. EUROPE, MIDDLE EAST & AFRICA GENOME TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 181. DENMARK GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 182. DENMARK GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 183. DENMARK GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. DENMARK GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 185. DENMARK GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 186. DENMARK GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 187. DENMARK GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 188. EGYPT GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. EGYPT GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 190. EGYPT GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 191. EGYPT GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 192. EGYPT GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 193. EGYPT GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. EGYPT GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. FINLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 196. FINLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 197. FINLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 198. FINLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 199. FINLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 200. FINLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 201. FINLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. FRANCE GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 203. FRANCE GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. FRANCE GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. FRANCE GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 206. FRANCE GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 207. FRANCE GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 208. FRANCE GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 209. GERMANY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 210. GERMANY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. GERMANY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. GERMANY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 213. GERMANY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 214. GERMANY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 215. GERMANY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 216. ISRAEL GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 217. ISRAEL GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 218. ISRAEL GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. ISRAEL GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 220. ISRAEL GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 221. ISRAEL GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 222. ISRAEL GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 223. ITALY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 224. ITALY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 225. ITALY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 226. ITALY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 227. ITALY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 228. ITALY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 229. ITALY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. NETHERLANDS GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 231. NETHERLANDS GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 232. NETHERLANDS GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. NETHERLANDS GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 234. NETHERLANDS GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 235. NETHERLANDS GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. NETHERLANDS GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 237. NIGERIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 238. NIGERIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 239. NIGERIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 240. NIGERIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 241. NIGERIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 242. NIGERIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 243. NIGERIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. NORWAY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 245. NORWAY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. NORWAY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. NORWAY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 248. NORWAY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 249. NORWAY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 250. NORWAY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 251. POLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 252. POLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. POLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. POLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 255. POLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 256. POLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 257. POLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 258. QATAR GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 259. QATAR GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 260. QATAR GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. QATAR GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 262. QATAR GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 263. QATAR GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 264. QATAR GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 265. RUSSIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 266. RUSSIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 267. RUSSIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 268. RUSSIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 269. RUSSIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 270. RUSSIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 271. RUSSIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 272. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 274. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 276. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 277. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. SAUDI ARABIA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 279. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 280. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 281. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 282. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 283. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 284. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 285. SOUTH AFRICA GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 286. SPAIN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 287. SPAIN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 288. SPAIN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. SPAIN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 290. SPAIN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 291. SPAIN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 292. SPAIN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 293. SWEDEN GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 294. SWEDEN GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 295. SWEDEN GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 296. SWEDEN GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 297. SWEDEN GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 298. SWEDEN GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 299. SWEDEN GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 300. SWITZERLAND GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 301. SWITZERLAND GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 302. SWITZERLAND GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. SWITZERLAND GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 304. SWITZERLAND GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 305. SWITZERLAND GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 306. SWITZERLAND GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 307. TURKEY GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 308. TURKEY GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. TURKEY GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. TURKEY GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 311. TURKEY GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 312. TURKEY GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 313. TURKEY GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 314. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 315. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 316. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 317. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 318. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 319. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 320. UNITED ARAB EMIRATES GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 321. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 322. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 323. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 324. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY CANCER, 2018-2030 (USD MILLION)
  • TABLE 325. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY NON-CANCER, 2018-2030 (USD MILLION)
  • TABLE 326. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 327. UNITED KINGDOM GENOME TESTING MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 328. GENOME TESTING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 329. GENOME TESTING MARKET, FPNV POSITIONING MATRIX, 2023